Learn about therapeutic and policy considerations in the medical use of cannabis from three expert instructors who have taught thousands of clinicians in state-approved certification courses. After a brief review of the endocannabinoid system and pharmacology, we focus on considerations around practice integration, risk management and addiction. How do you discuss potential drug interactions, adverse events, and cannabis use disorder with patients? What protocols should be in place for your facility, program, or hospital? We discuss regulatory concerns and controversies, including the impact of cannabis legalization on the drug overdose crisis, and leave plenty of time for questions.
Christine Roussel, PharmD, BCOP is a Board-certified Oncology Pharmacist with a bachelor’s degree in Toxicology and a doctorate in Pharmacy from University of the Sciences in Philadelphia. Her passions include occupational exposure to hazardous drugs, compounding and legislative topics, such as medical cannabis. Dr Roussel is Director of Pharmacy at Doylestown Hospital, co-founder of the American Society of Cannabis Pharmacists, course director of a DOH-approved 4-hour medical cannabis course, and a popular lecturer nationally and regionally.
Adam C. Lake, MD, FAAFP, AAHIVS, FACMQ practices at Penn LGHealth in Lancaster, where he is on the faculty of the family medicine residency program. His areas of expertise include addiction medicine, HIV/AIDS, Hep-C, and lesbian, gay, bisexual, and transgender health. Dr Lake studied linguistics & biochemistry at Grinnell College, medicine at Temple University, permaculture & traditional medicine in Latin America, & completed a fellowship in population health. Dr Lake is a registered physician in the PA Medical Marijuana program, and lectures locally and regionally on treatment of opioid use disorder and medical marijuana.
Gail Groves Scott, MPH is a opioid use disorder policy researcher, doctoral student, and public health consultant. She researches access to treatment medications, as well as the impact of the pharmaceutical industry on medical education and policy. Gail launched the University of the Sciences’ Substance Use Disorders Institute in 2018-19, and managed their medical cannabis continuing education training approved by the Pennsylvania Department of Health to certify medical professionals. A whistleblower in a record-setting Department of Justice case, Gail was a pharma sales representative for more than 16 years prior to changing careers to work in public health policy.